Themis Medicare Limited (THEMISMED.BO)
INR 273.3
(0.64%)
INR 273.3
(0.64%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 782.85 Million INR | -36.99% |
| 2022 | 1.76 Billion INR | 12.72% |
| 2021 | 1.56 Billion INR | 43.3% |
| 2020 | 1.09 Billion INR | -0.07% |
| 2019 | 1.09 Billion INR | -8.9% |
| 2018 | 1.19 Billion INR | 1.05% |
| 2017 | 1.18 Billion INR | -0.09% |
| 2016 | 1.18 Billion INR | 8.49% |
| 2015 | 1.09 Billion INR | 18.11% |
| 2014 | 927.04 Million INR | -1.22% |
| 2013 | 938.47 Million INR | 11.15% |
| 2012 | 844.3 Million INR | 6.93% |
| 2011 | 789.56 Million INR | 224.93% |
| 2010 | 242.99 Million INR | 742.91% |
| 2009 | 28.82 Million INR | 286.95% |
| 2008 | 7.45 Million INR | -63.18% |
| 2007 | 20.23 Million INR | -35.79% |
| 2006 | 31.51 Million INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 606.98 Million INR | 9.43% |
| 2024 Q1 | 309.53 Million INR | 15.35% |
| 2023 Q2 | 535.07 Million INR | 9.51% |
| 2023 Q3 | 510.58 Million INR | -4.58% |
| 2023 Q4 | 268.34 Million INR | -47.44% |
| 2023 FY | 1.11 Billion INR | -36.99% |
| 2023 Q1 | 488.61 Million INR | -59.37% |
| 2022 Q4 | 1.2 Billion INR | 523.21% |
| 2022 Q1 | 469.27 Million INR | 26.23% |
| 2022 FY | 1.76 Billion INR | 12.72% |
| 2022 Q2 | 447.02 Million INR | -4.74% |
| 2022 Q3 | 192.94 Million INR | -56.84% |
| 2021 Q4 | 371.77 Million INR | 138.37% |
| 2021 Q1 | 328.69 Million INR | 12.78% |
| 2021 FY | 1.56 Billion INR | 43.3% |
| 2021 Q2 | 451.03 Million INR | 37.22% |
| 2021 Q3 | 155.96 Million INR | -65.42% |
| 2020 Q4 | 291.43 Million INR | -2.03% |
| 2020 Q3 | 297.46 Million INR | 2.62% |
| 2020 FY | 1.09 Billion INR | -0.07% |
| 2020 Q1 | 213.11 Million INR | -14.41% |
| 2020 Q2 | 289.88 Million INR | 36.02% |
| 2019 Q2 | 282.63 Million INR | 0.56% |
| 2019 Q4 | 248.99 Million INR | -11.04% |
| 2019 Q1 | 281.07 Million INR | -3.9% |
| 2019 FY | 1.09 Billion INR | -8.9% |
| 2019 Q3 | 279.9 Million INR | -0.97% |
| 2018 Q3 | 291.29 Million INR | -4.14% |
| 2018 Q2 | 303.85 Million INR | -2.51% |
| 2018 Q1 | 311.68 Million INR | 4.35% |
| 2018 FY | 1.19 Billion INR | 1.05% |
| 2018 Q4 | 292.47 Million INR | 0.41% |
| 2017 Q4 | 298.68 Million INR | -5.39% |
| 2017 FY | 1.18 Billion INR | -0.09% |
| 2017 Q2 | 275.3 Million INR | 0.0% |
| 2017 Q3 | 315.71 Million INR | 14.68% |
| 2016 Q3 | 249.78 Million INR | -31.59% |
| 2016 FY | 1.18 Billion INR | 8.49% |
| 2016 Q2 | 365.13 Million INR | 13.82% |
| 2016 Q1 | 320.79 Million INR | 13.09% |
| 2016 Q4 | 287.49 Million INR | 15.1% |
| 2015 Q1 | 261.09 Million INR | -31.71% |
| 2015 Q3 | 293.06 Million INR | -1.92% |
| 2015 Q4 | 283.64 Million INR | -3.21% |
| 2015 FY | 1.09 Billion INR | 18.11% |
| 2015 Q2 | 298.8 Million INR | 14.44% |
| 2014 Q3 | 149.08 Million INR | -38.87% |
| 2014 FY | 927.04 Million INR | -1.22% |
| 2014 Q2 | 243.89 Million INR | 0.0% |
| 2014 Q4 | 382.36 Million INR | 156.47% |
| 2013 FY | 938.47 Million INR | 11.15% |
| 2012 Q1 | 26.7 Million INR | 0.0% |
| 2012 FY | 844.3 Million INR | 6.93% |
| 2012 Q3 | 67.06 Million INR | -1.61% |
| 2012 Q2 | 68.16 Million INR | 155.19% |
| 2012 Q4 | 678 Million INR | 911.03% |
| 2011 FY | 789.56 Million INR | 224.93% |
| 2010 FY | 242.99 Million INR | 742.91% |
| 2009 FY | 28.82 Million INR | 286.95% |
| 2008 FY | 7.45 Million INR | -63.18% |
| 2007 FY | 20.23 Million INR | -35.79% |
| 2006 FY | 31.51 Million INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Ajanta Pharma Limited | 30.46 Billion INR | 97.43% |
| Amrutanjan Health Care Limited | 1.09 Billion INR | 28.766% |
| Sigachi Industries Limited | 579.88 Million INR | -35.001% |
| Bal Pharma Limited | 389.89 Million INR | -100.789% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | 63.146% |
| Medico Remedies Limited | 161.84 Million INR | -383.71% |
| Lasa Supergenerics Limited | 291.17 Million INR | -168.862% |
| Venus Remedies Limited | 1.91 Billion INR | 59.147% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 74.556% |
| Alpa Laboratories Limited | 156.14 Million INR | -401.358% |
| Nectar Lifesciences Limited | 625.55 Million INR | -25.147% |
| Shilpa Medicare Limited | 2.18 Billion INR | 64.099% |
| Aarti Drugs Limited | 1.16 Billion INR | 32.945% |
| Lupin Limited | 95.67 Billion INR | 99.182% |
| Aurobindo Pharma Limited | 39.23 Billion INR | 98.005% |
| Zydus Lifesciences Limited | 43.17 Billion INR | 98.187% |
| Windlas Biotech Limited | 1 Billion INR | 22.221% |
| Suven Life Sciences Limited | 109.75 Million INR | -613.308% |
| Eris Lifesciences Limited | 4.94 Billion INR | 84.162% |
| Valiant Laboratories Limited | 36.28 Million INR | -2057.279% |
| J. B. Chemicals & Pharmaceuticals Limited | 8.41 Billion INR | 90.699% |
| Solara Active Pharma Sciences Limited | 4.57 Billion INR | 82.906% |
| Ipca Laboratories Limited | 13.91 Billion INR | 94.374% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | 44.839% |
| Achyut Healthcare Limited | 1.6 Million INR | -48554.755% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.492% |
| Bajaj HealthCare Limited | 985.34 Million INR | 20.55% |
| RPG Life Sciences Limited | 1.63 Billion INR | 52.134% |
| Mankind Pharma Limited | 23.15 Billion INR | 96.619% |
| Laurus Labs Limited | 3.01 Billion INR | 73.998% |
| Piramal Pharma Limited | 19.91 Billion INR | 96.069% |
| Syncom Formulations (India) Limited | 942.39 Million INR | 16.93% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 96.346% |
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | 95.067% |
| Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 98.841% |
| Unichem Laboratories Limited | 6.72 Billion INR | 88.361% |
| Sequent Scientific Limited | 2.9 Billion INR | 73.022% |
| Novartis India Limited | 470.1 Million INR | -66.529% |
| Wanbury Limited | 1.16 Billion INR | 32.566% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | 44.193% |
| Wockhardt Limited | 6.4 Billion INR | 87.768% |
| Jagsonpal Pharmaceuticals Limited | 773.41 Million INR | -1.221% |
| Jubilant Pharmova Limited | 14.45 Billion INR | 94.584% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | 93.275% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 99.183% |
| Divi's Laboratories Limited | 14.17 Billion INR | 94.475% |
| NATCO Pharma Limited | 10.05 Billion INR | 92.217% |
| Gufic Biosciences Limited | 1.07 Billion INR | 27.359% |
| IOL Chemicals and Pharmaceuticals Limited | 1.09 Billion INR | 28.754% |
| Ind-Swift Limited | 946.56 Million INR | 17.295% |
| Procter & Gamble Health Limited | 2.99 Billion INR | 73.865% |
| FDC Limited | 5.34 Billion INR | 85.363% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -1596.107% |
| Granules India Limited | 7.18 Billion INR | 89.1% |
| Medicamen Biotech Limited | 335.16 Million INR | -133.572% |
| Alkem Laboratories Limited | 32.83 Billion INR | 97.616% |
| AstraZeneca Pharma India Limited | 2.6 Billion INR | 69.895% |
| Biofil Chemicals and Pharmaceuticals Limited | 16.2 Million INR | -4729.547% |
| Brooks Laboratories Limited | 51.18 Million INR | -1429.611% |
| Megasoft Limited | 49.52 Million INR | -1480.631% |
| ZIM Laboratories Limited | 1.01 Billion INR | 22.724% |
| Strides Pharma Science Limited | 9.16 Billion INR | 91.456% |
| Neuland Laboratories Limited | 2.92 Billion INR | 73.279% |
| Morepen Laboratories Limited | 1.98 Billion INR | 60.61% |
| Hikal Limited | 2.48 Billion INR | 68.514% |
| Indoco Remedies Limited | 4.74 Billion INR | 83.515% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | 74.536% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | -89.817% |
| Mangalam Drugs & Organics Limited | 676.14 Million INR | -15.782% |
| Hester Biosciences Limited | 908.84 Million INR | 13.862% |